BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
BridgeBio Pharma announced the publication of its Phase 3 PROPEL 3 clinical trial results for oral infigratinib, a treatment for children with achondroplasia, in the New England Journal of Medicine. The trial showed statistically significant improvements in height velocity, body proportionality, and arm span versus placebo, marking important milest…